Skip to Content
Merck
All Photos(2)

Documents

B3170

Sigma-Aldrich

Monoclonal Anti-Bcl-2 antibody produced in mouse

clone Bcl-2-100, ascites fluid

Synonym(s):

Anti-BCL-2

Sign Into View Organizational & Contract Pricing


About This Item

MDL number:
UNSPSC Code:
12352203
NACRES:
NA.41

biological source

mouse

Quality Level

conjugate

unconjugated

antibody form

ascites fluid

antibody product type

primary antibodies

clone

Bcl-2-100, monoclonal

mol wt

antigen 26 kDa

contains

15 mM sodium azide

species reactivity

human

should not react with

mouse

technique(s)

electron microscopy: suitable
immunocytochemistry: suitable
immunohistochemistry (formalin-fixed, paraffin-embedded sections): suitable
immunohistochemistry (frozen sections): suitable
immunoprecipitation (IP): suitable
microarray: suitable
western blot: 1:1,000 using human HeLa cell extract

isotype

IgG1

UniProt accession no.

shipped in

dry ice

storage temp.

−20°C

target post-translational modification

unmodified

Gene Information

human ... BCL2(596)

General description

BCL2 (B-cell lymphoma 2) consists of pro- and antiapoptotic functions. It belongs to BCL2 family of proteins. It is mapped to human chromosome 18q21.3.

Immunogen

synthetic peptide corresponding to residues 41-54 of the Bcl-2 protein, conjugated to thyroglobulin.

Application

Anti-BCL2 (Ab-56) antibody has been used in western blotting and immunocytochemistry.
Applications in which this antibody has been used successfully, and the associated peer-reviewed papers, are given below.
Western Blotting (1 paper)
Monoclonal Anti-Bcl-2 antibody produced in mouse is suitable for western blotting at a concentration of 1:1,000 by using human HeLa cell extract. It is also suitable for immunohistochemistry by using formalin-fixed, paraffin-embedded tissue sections or frozen sections. Further, the antibody may be used for the localization of Bcl-2, by implementing numerous assays like- microarray, electron microscopy and immunoprecipitation.

Biochem/physiol Actions

BCL2 (B-cell lymphoma 2) plays an important role in the growth and progression of cancer. Overexpression of BCL2 (B-cell lymphoma 2) results in poor clinical predictions in diffuse large B-cell lymphoma (DLBCL). Bcl2 is highly essential for the survival of kidney and melanocyte stem cells and mature lymphocytes. It may control Bcl2 multiple initiator caspases.
Protooncogene BCL2 encodes a 26 kD integral outer mitochondrial membrane protein expressed in sub-cellular components such as the mitochondria and nucleus. While mitochondrial BCL2 inhibits apoptosis, BCL2 present in the nucleus may activate cell death. It may also regulate autophagy during starvation. Additionally, BCL2 facilitates the survival of central and peripheral neurons grown in culture in the absence of neurotrophic factors.

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Not finding the right product?  

Try our Product Selector Tool.

Storage Class Code

10 - Combustible liquids

WGK

nwg

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable


Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

BCL2 genotypes and prostate cancer survival
Renner W, et al.
Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [Et Al], 193(6), 466-471 (2017)
Long non-coding RNA Igf2as controls hepatocellular carcinoma progression through the ERK/MAPK signaling pathway
Bao H, et al.
Oncology Letters, 14(3), 2831-2837 (2017)
The protein PprI provides protection against radiation injury in human and mouse cells
Shi Y, et al.
Scientific Reports (2016)
Raquel Vinhas et al.
Molecular therapy. Nucleic acids, 7, 408-416 (2017-06-19)
Introduction of tyrosine kinase inhibitors for chronic myeloid leukemia treatment is associated with a 63% probability of maintaining a complete cytogenetic response, meaning that over 30% patients require an alternative methodology to overcome resistance, tolerance, or side effects. Considering the
BCL2 expression in DLBCL: reappraisal of immunohistochemistry with new criteria for therapeutic biomarker evaluation
Tsuyama N, et al.
Blood, 130(4), 489-500 (2017)

Articles

Quantitative and qualitative western blotting to validate knockdown by esiRNA.

Quantitative and qualitative western blotting to validate knockdown by esiRNA.

Quantitative and qualitative western blotting to validate knockdown by esiRNA.

Quantitative and qualitative western blotting to validate knockdown by esiRNA.

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service